Virax Biolabs increased the maximum aggregate amount of ordinary shares it may sell through H.C. Wainwright to $2,070,060.20, excluding $3,658,152 previously sold under the agreement. The change gives investors a larger stated share-sale capacity under the existing arrangement, subject to applicable securities-law registration or qualification requirements.

Key Highlights

  • Virax Biolabs entered its At The Market Offering Agreement with H.C. Wainwright on January 22, 2024.
  • The ordinary shares carry a Par Value of $0.025 per share.
  • The prospectus supplement amending the offering was dated September 4, 2026.

Virax Biolabs Group Ltd (NASDAQ: VRAX) increased the maximum aggregate value of ordinary shares available for sale under its At The Market Offering Agreement to $2,070,060.20.

Prospectus Sets Offering Terms

H.C. Wainwright & Co. LLC serves as Virax Biolabs’ sales agent under the agreement, which permits the company to offer ordinary shares from time to time. The securities have a par value of $0.025 per share. The arrangement was established on January 22, 2024. The updated prospectus supplement amends materials dated January 22, 2024, September 30, 2024, and December 15, 2023. Those documents form part of Virax Biolabs’ effective registration statement, identified by File No. 333-275893.

Expanded Capacity Governs Future Sales

The revised ceiling gives Virax Biolabs the stated ability to conduct additional ordinary-share sales through H.C. Wainwright under the existing Sales Agreement. The $2,070,060.Any offer, solicitation or sale remains subject to registration or qualification requirements under applicable securities laws.